Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) Meeting Abstract
| Authors: | Kopetz, S.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H. S.; Yoshino, T.; Desai, J.; Ciardiello, F.; Loupakis, F.; Hong, Y. S.; Steeghs, N.; Guren, T. K.; Arkenau, H. T.; Garcia-Alfonso, P.; Gollerkeri, A.; Maharry, K.; Christy-Bittel, J.; Keir, C. H.; Pickard, M. D.; Tabernero, J. |
| Abstract Title: | Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Start Page: | 214s |
| Language: | English |
| ACCESSION: | WOS:000560368302017 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.4039 |
| Notes: | Meeting Abstract: 4039 -- Source: Wos |
